Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases

Data from American Urological Association 2017 Annual Meeting Establishes Oncotype DX as First Genomic Prostate Cancer Test to Predict Both Near-term Adverse Pathology and Long-term Outcomes

News provided by

Genomic Health, Inc.

May 04, 2017, 08:00 ET

REDWOOD CITY, Calif., May 4, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from four new Oncotype DX^® Genomic Prostate Score™ (GPS) studies will be presented at the upcoming American Urological Association (AUA) 2017 Annual Meeting, which will be held May 12-16 in Boston. With new results reporting the performance of the GPS in assessing risk and long-term outcomes in patients across various stages of prostate cancer, GPS is now the only test to provide an assessment of the current state of a man's cancer via adverse pathology, as well as his individualized risk of developing metastasis or dying of prostate cancer within 10 years.

The poster discussions will include:

Results from a study performed using tissue samples from a patient database from Kaiser Permanente's Northern California region that examine GPS performance in predicting biochemical recurrence, prostate cancer-specific death and metastasis in patients with clinically low-, intermediate- and high-risk prostate cancer who were treated with radical prostatectomy;
Results of a prospective, multi-site study that evaluated GPS as a predictor of adverse pathology in men treated with radical prostatectomy for clinically low-risk prostate cancer;
Interim results examining clinical utility from a study evaluating GPS impact on rates of active surveillance utilization and persistence; and
Results from a study conducted at six Veterans Affairs medical centers that compared treatment patterns before and after introduction of GPS to determine if the test improves risk stratification and the use of active surveillance.

Complete results of the studies will be presented as follows (all times are in Eastern Daylight Time) and abstracts are now available at http://www.aua2017.org/abstracts/.

Friday, May 12

Abstract: MP20-05
Moderated Poster: "A diagnostic biopsy-based Genomic Prostate Score as an independent predictor of prostate cancer death and metastasis in men with localized prostate cancer"
Authors: Van Den Eeden S, Zhang N, Shan J, Quesenberry C, Han J, Tsiatis A, Lu R, Lawrence J, Febbo P, Presti J.
Location: BCEC Room 160
Time: 3:30 – 5:30 p.m.

Saturday, May 13

Abstract: MP28-01
Moderated Poster: "A 17-gene panel for prediction of adverse pathology at radical prostatectomy: prospective validation"
Authors: Eggener S, Richardson T, Rosenberg S, Goldfischer E, Lu R, Shindel A, Bennett J, Karsh L, Korman H, Febbo P, Denes B.
Location: BCEC Room 253AB
Time: 7 – 9 a.m.
Abstract: MP28-11
Moderated Poster: "Impact of the 17-gene panel on active surveillance persistence in contemporary urologic practices: an interim analysis in an observational cohort"
Authors: Eure G, Germany R, Given R, Glowacki R, Richardson T, Goldfischer E, Lu R, Shindel A, Bennett J. Febbo P, Denes B.
Location: BCEC Room 253AB
Time: 7 – 9 a.m.

Monday, May 15

Abstract: MP86-16
Moderated Poster: "A multi-center analysis of prostate cancer (PCa) treatment among Veterans following introduction of the 17-gene Genomic Prostate Score (GPS) assay"
Authors: Dash A, Lynch J, Rothney M, Salup R, Ercole C, Mathur S, Duchene D, Basler J, Hernandez J, Liss M, Porter M, Wright JL.
Location: BCEC Room 156
Time: 3:30 – 5:30 p.m.

About the Oncotype DX^® Genomic Prostate Score™
Designed by Genomic Health based on results from multiple studies led by Cleveland Clinic and the University of California, San Francisco, the Oncotype DX Genomic Prostate Score analyzes 17 genes across four biological pathways from tumor tissue removed during biopsy to provide an individual score that, in combination with other clinical factors, further clarifies a man's risk prior to treatment intervention. The test enables confident treatment decisions to provide the opportunity for low-risk patients to avoid prostatectomy or radiation - and their side effects - while identifying men who need immediate definitive treatment. To learn more about the Oncotype DX Genomic Prostate Score, visit www.OncotypeDX.com or www.MyProstateCancerTreatment.org.

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ^® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ^® Liquid Select™. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our business model; the applicability of clinical study results to actual outcomes; the impact of results from clinical studies on market adoption of Oncotype DX tests, our ability to develop and commercialize new tests and expand into new markets domestically and internationally; unanticipated costs or delays in research and development efforts; and other risks and uncertainties set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-P

SOURCE Genomic Health, Inc.